POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS
(2025)
Presentation / Conference Contribution
Makos, A., Grime, H., Amarasena, R., Kuiper, J., & Kehoe, O. POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS. Presented at EULAR 2024, Vienna, Austria
Background:
Psoriatic Arthritis (PsA) is a complex immune-mediated disease. TNF inhibitors (TNFi) are the first-line biologic drugs to treat PsA, targeting soluble TNF-α (sTNF) and membrane-bound TNF-α (mTNF). TNF...
Read More about POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS.